Pancreatic cancer pill shown to nearly double overall survival time, drug company says

(NewsNation) — A pancreatic cancer drug is showing promising signs of a possible breakthrough after a clinical trial found it nearly doubled the length of survival among patients.

In a press release Monday, Revolution Medicines shared the findings of its Phase 3 clinical trial, which evaluated the drug Daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma who had been previously treated.

The company reports the drug, taken orally once a day, showed “clinically meaningful improvements” in progression-free survival and overall survival compared with standard-of-care cytotoxic chemotherapy delivered intravenously. Specifically, the drug showed a median overall survival of 13.2 months compared to 6.7 months for chemotherapy.

“For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and improve quality of life,” Dr. Brian M. Wolpin, principal investigator for the RASolute 302 trial, said.

He added, “I believe that this new approach is a very important advance for the field that I expect will be practice-changing for physicians and improve the care for patients with previously treated metastatic pancreatic cancer.”

The drug is designed to stop RAS mutations, which drive tumor growth and are found in 90% of pancreatic cancer cases.

According to the Pancreatic Cancer Action Network, the five-year survival rate for pancreatic cancer remains flat at 13 percent and just 8 percent for people diagnosed with the most common form of pancreatic cancer, pancreatic adenocarcinoma.

Revolution Medicines says it intends to submit the findings of this trial to global regulatory authorities, including the Food and Drug Administration, as part of a future New Drug Application under a Commissioner’s National Priority Voucher.

Copyright 2026 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

More Health Care News

GOP senators grow uncomfortable with Trump rhetoric, endgame for Iran

Swalwell, Gonzales exits shift spotlight to other embattled lawmakers

McConnell chides ‘some’ on right over failed campaigning for Orban in ...

Cook Political Report shifts 4 Senate races toward Democrats

Expulsion threats force out two House members; Two more hang in balance

Trump angers Catholics in targeting Pope Leo XIV over Iran war pushback 

The Supreme Court’s refusal to stand up for press freedom is catastrophic

Trump’s gauge on gas prices spurs GOP anxieties ahead of midterms

New York, California compete as disaster tourism destinations for economists

Anthropic’s Mythos puts DC, Wall Street on high alert

‘This is the last warning:’ Iran radioes US during Strait of Hormuz ...

Trump-as-Jesus post angers Christian conservatives who say it’s ...

MAGA break with Trump on Iran is imaginary

Janelle Stelson hauls in more than $2.1M in Q1 in House race against Scott ...

Garcia threatens Bondi with contempt on Tuesday

Tony Gonzales says he’ll ‘file my retirement,’ following Swalwell ...

Trump on AI Jesus image: ‘I thought it was me as a doctor’

The Memo: Trump rolls the dice with blockade of Iran

The Hill Podcasts – Morning Report

© The Hill